BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23449702)

  • 1. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.
    Bergamaschi MM; Karschner EL; Goodwin RS; Scheidweiler KB; Hirvonen J; Queiroz RH; Huestis MA
    Clin Chem; 2013 Mar; 59(3):519-26. PubMed ID: 23449702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
    Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
    Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
    Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
    Schwope DM; Karschner EL; Gorelick DA; Huestis MA
    Clin Chem; 2011 Oct; 57(10):1406-14. PubMed ID: 21836075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?
    Desrosiers NA; Lee D; Concheiro-Guisan M; Scheidweiler KB; Gorelick DA; Huestis MA
    Clin Chem; 2014 Feb; 60(2):361-72. PubMed ID: 24185550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
    Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
    Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.
    Milman G; Schwope DM; Schwilke EW; Darwin WD; Kelly DL; Goodwin RS; Gorelick DA; Huestis MA
    Clin Chem; 2011 Nov; 57(11):1597-606. PubMed ID: 21875944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.
    Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Herning RI; Cadet JL; Huestis MA
    J Anal Toxicol; 2009 Oct; 33(8):469-77. PubMed ID: 19874654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.
    Anizan S; Milman G; Desrosiers N; Barnes AJ; Gorelick DA; Huestis MA
    Anal Bioanal Chem; 2013 Oct; 405(26):8451-61. PubMed ID: 23954944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fitness to drive and cannabis: validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers.
    Fabritius M; Augsburger M; Chtioui H; Favrat B; Giroud C
    Forensic Sci Int; 2014 Sep; 242():1-8. PubMed ID: 24999608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney GR; Huestis MA
    Clin Chem; 2016 Feb; 62(2):367-77. PubMed ID: 26823611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.
    Lowe RH; Abraham TT; Darwin WD; Herning R; Cadet JL; Huestis MA
    Drug Alcohol Depend; 2009 Nov; 105(1-2):24-32. PubMed ID: 19631478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?
    Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Pope HG; Herning R; Cadet JL; Huestis MA
    Addiction; 2009 Dec; 104(12):2041-8. PubMed ID: 19804462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.
    Lee D; Bergamaschi MM; Milman G; Barnes AJ; Queiroz RH; Vandrey R; Huestis MA
    J Anal Toxicol; 2015 Oct; 39(8):580-7. PubMed ID: 26378131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.
    Lee D; Vandrey R; Mendu DR; Murray JA; Barnes AJ; Huestis MA
    Drug Test Anal; 2015 Jun; 7(6):494-501. PubMed ID: 25220020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration.
    Milman G; Barnes AJ; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
    Anal Bioanal Chem; 2011 Aug; 401(2):599-607. PubMed ID: 21637933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
    Schwilke EW; Schwope DM; Karschner EL; Lowe RH; Darwin WD; Kelly DL; Goodwin RS; Gorelick DA; Huestis MA
    Clin Chem; 2009 Dec; 55(12):2180-9. PubMed ID: 19833841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
    Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
    Clin Chem; 2015 Jun; 61(6):850-69. PubMed ID: 26019183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.
    Lee D; Vandrey R; Mendu DR; Anizan S; Milman G; Murray JA; Barnes AJ; Huestis MA
    Clin Chem; 2013 Dec; 59(12):1770-9. PubMed ID: 23938457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.